Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News ASBESTOS CORPORATION LIMITED V.AB.H

Asbestos Corp Ltd is a Canada-based company which is engaged in maintaining mining assets. It generates revenue from Canada. The company derives key revenue from building rental and royalties. Other revenue sources comprises investment income and other revenue from mining properties.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (TSXV:AB.H)

Fundamentals Snapshot (TSXV:AB.H)

Current News (TSXV:AB.H)

Asbestos Corporation Limited Announces Changes to its Board of Directors

Canada NewsWire May 26, 2022

Strategic partnership between a subsidiary of Asbestos Corporation Limited and ECO2 Magnesia Inc.

PR Newswire August 30, 2021

AB Science announces issuance of a new European patent for protecting the use of masitinib in pancreatic cancer patients

GlobeNewswire July 12, 2017

AB Science Presents Supportive Data from its Phase 3 Study in Severe Systemic Mastocytosis at the 22nd Congress of the European Hematology Association (EHA)

GlobeNewswire June 22, 2017

AB Science presents phase 3 data for masitinib in amyotrophic lateral sclerosis (ALS) at the European Network for the Cure of ALS (ENCALS) annual meeting

GlobeNewswire May 18, 2017

AB Science announces that CHMP has adopted a negative opinion for masitinib in indolent systemic mastocytosis, primarily due to GCP inspection findings

GlobeNewswire May 17, 2017

AB Science provides the summary of both conference calls held on May 12, 2017, following ANSM decision requesting suspension of masitinib clinical studies conducted in France by AB Science

GlobeNewswire May 15, 2017

AB Science announces publication in The Lancet of phase 3 clinical trial results demonstrating masitinib is effective and well tolerated in the treatment of adult patients with mastocytosis

GlobeNewswire January 9, 2017

AB Science announces that new preclinical data demonstrate that masitinib has an unexpected protective effect on muscles and nerves in amyotrophic lateral sclerosis

GlobeNewswire January 3, 2017

Opinion & Analysis (TSXV:AB.H)

No current opinion is available.

Bullboard Posts (TSXV:AB.H)

test

[img]https://http://teuton.com/wp-content/uploads/2019/08/DNW-01gr.jpg[/img]
Olympia2 - October 25, 2019

New Federal Government Rules & Regulatios - Tailings Exempt

New Federal Government Rules & Regulatios - Tailings Exempt From The Canadian Press, January 5, 2018 “The clean-up of millions...
RTO - January 6, 2018